<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">507</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2019-95-4-79-86</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DRUG TREATMENT IN DERMATOVENEROLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Fulminant acne. Modern solution of the problem</article-title><trans-title-group xml:lang="ru"><trans-title>Фульминантные акне. Современное решение проблемы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Drozhdina</surname><given-names>M. B.</given-names></name><name xml:lang="ru"><surname>Дрождина</surname><given-names>М. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Assoc. Prof., Department of Dermatovenerology and Cosmetology,</p><p>Karla Marksa str., 112, Kirov, 610998</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры дерматовенерологии и косметологии,</p><p>610998, г. Киров, у л. Карла Маркса, д. 112</p></bio><email>drozhdina@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kirov State Medical University, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Кировский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-08-19" publication-format="electronic"><day>19</day><month>08</month><year>2019</year></pub-date><volume>95</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>79</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2019-10-19"><day>19</day><month>10</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-10-19"><day>19</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Drozhdina M.B.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Дрождина М.Б.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Drozhdina M.B.</copyright-holder><copyright-holder xml:lang="ru">Дрождина М.Б.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/507">https://vestnikdv.ru/jour/article/view/507</self-uri><abstract xml:lang="en"><p>Modern ideas about the etiological factors underlying a rare, serious illness — fulminant acne, the influence of genetic and exposure factors on the formation of the disease, and the pathogenesis of this form of acne are described. The main pathogenetic factors affecting the debut and course of fulminant acne were identified: Cutibacterium and the microbiome of the skin as a whole; sebum overproduction of sebum with the direct participation of dihydrotestosterone, progesterone, insulin-like growth factor-1; features of innate immunity, follicular hyperkeratosis. The clinic, complications and optimal therapeutic tactics at the present stage are described. A clinical case with a successful therapeutic outcome is presented.</p></abstract><trans-abstract xml:lang="ru"><p>Описаны современные представления об этиологических факторах, лежащих в основе редкого, тяжелого заболевания — фульминантных акне, влиянии генетических и экспосом-факторов на формирование заболевания, особенностях патогенеза данной формы акне. Выделены основные патогенетические факторы, влияющие на дебют и течение фульминантных акне: Cutibacterium и микробиом кожных покровов в целом; гиперпродукция кожного сала себоцитами при непосредственном участии дигидротестостерона, прогестерона, инсулиноподобного фактора роста-1; особенности врожденного иммунитета, фолликулярный гиперкератоз. Описаны клиника, осложнения и оптимальная терапевтическая тактика на современном этапе. Представлен клинический случай с успешным терапевтическим исходом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>fulminant acne</kwd><kwd>Cutibacterium</kwd><kwd>exposome</kwd><kwd>microbiome</kwd><kwd>dihydrotestosterone</kwd><kwd>progesterone</kwd><kwd>insulin-like growth factor-1</kwd><kwd>isotretinoin Lidose</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фульминантные акне</kwd><kwd>Cutibacterium</kwd><kwd>экспосом</kwd><kwd>микробиом</kwd><kwd>дигидротестостерон</kwd><kwd>прогестерон</kwd><kwd>инсулиноподобный фактор роста-1</kwd><kwd>изотретиноин Lidose</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Dreno B., Pecastaings S., Corvec S. et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl 2):5–14. DOI: 10.1111/jdv.15043</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Palatsi R., Oikarinen A. Hormonal analysis and delayed hypersensitivity reactions in identical twins with severe acne. Acta Derm Venereol. 1979;59(2):157–160.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Lynn D. D., Umari T., Dunnick C. A., Dellavalle R. P. The epidemiology of acne vulgaris in late adolescence. Adolescent Health Med Ther. 2016;7:13–25. DOI: 10.2147/AHMT.S55832</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Zhang M., Qureshi A. A., Hunter D. J., Han J. A genome-wide association study of severe teenage acne in European Americans. Human genetics. 2014;33(3):259–264. DOI: 10.1007/s00439-013-1374-4</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol. 1989 Apr;125(4):571–572. DOI: 10.1001/archderm.125.4.571b</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Wollina U., Gesina H., Koch A., Kostler E. Case reports: acne fulminans in Marfan syndrome. J Drugs Dermatol. 2005 Jul-Aug;4(4):501–505.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Dreno B., Bettoli V., Araviiskaia E. et al. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32:812–819. DOI: 10.1111/jdv.14820</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Murillo N., Raoult D. Skin microbiota: overview and role in the skin diseases acne vulgaris and rosacea. Future Microbiol. 2013;8:209– 222. DOI: 10.2217/fmb.12.141</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Wolf R., Parish L. C. Effect of soaps and detergents on epidermal barrier function. Clin Dermatol. 2012;30:297–300. DOI: 10.1016/j.clindermatol.2011.08.021</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Матушевская Е. В., Антонова Л. А., Матушевская Ю. И., Петрова К. С. Клинический опыт применения системного изотретиноина в лечении тяжелых форм акне. РМЖ. 2018;82(II):109–112.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Nagy I., Pivarcsi A., Kis K. et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 2006;8:2195–2205. DOI: 10.1016/j.micinf.2006.04.001</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Placzek M., Degitz K., Schmidt H., Plewig G. Acne fulminans in late-onset congenital adrenal hyperplasia. Lancet. 1999 Aug 28;354(9180):739–740. DOI: 10.1016/S0140-6736(99)01862-0</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Hoyt G., Hickey M. S., Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr. 2005;93:175–177. DOI: 10.1079/BJN20041304</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Honma M., Murakami M., Iinuma S. et al. Acne fulminans following measles infection. J Dermatol. 2009 Aug;36(8):471–473. DOI: 10.1111/j.1346-8138.2009.00680.x</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Brănişteanu D. E., Cotrutz C. E., Luca M. C., Molodoi D. A., Stoica L. E., Ianoşi S. L. et al. Morphopathological stigmata in acne fulminans. Rom J Morphol Embryol. 2015;56(3):1185–1190.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Dreno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):8–12. DOI: 10.1111/jdv.14374</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Greywal T. L., Zaenglein A., Baldwin H., Bhatia N., Chernoff K. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol. 2017 Jul;77(1):109–117. DOI: 10.1016/j.jaad.2016.11.028</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Wakabayashi M., Fujimoto N., Uenishi T., Danno K., Tanaka T. A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease. Dermatology. 2011;222(3):231– 235. DOI: 10.1159/000324226</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Williamson D. M., Cunliffe W. J., Gatecliff M., Scott D. G. Acute ulcerative acne conglobata (acne fulminans) with erythema nodosum. Clin Exp Dermatol. 1977 Dec;2(4):351–354. DOI: 10.1111/j.1365-2230.1977.tb01574.x</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Kim S. Y., Jung S. K., Lee S. G., Yi S. M., Kim J. H., Kim I. H. Acne fulminans with osteolytic change in metaphysis of distal radius. Int J Dermatol. 2016 May;55(5):571–573.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Gordon P. M., Farr P. M., Milligan A. Acne fulminans and bone lesions may present to other specialties. Pediatr Dermatol. 1997 NovDec;14(6):446–448. DOI: 10.1111/j.1525-1470.1997.tb00686.x</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Iqbal M., Kolodney M. S. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005 May;52(5. Suppl 1):S118–S120. DOI: 10.1016/j. jaad.2004.09.006</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Kraus S. L., Emmert S., Schön M. P., Haenssle H. A. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. Oct 2012;148(10):1210–1212. DOI: 10.1001/archdermatol.2012.855</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol. 1989 Apr;125(4):571–572. DOI: 10.1001/archderm.125.4.571b</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Siadat A. H., Bostakian A., Abtahi-Naeini B., Shahbazi M. Successful Treatment of Facial Acne Fulminans: Antimicrobial Agents and Oral Prednisolone as Promising Regimes. Case Rep Dermatol Med. 2017;2017:7092910. DOI: 10.1155/2017/7092910</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Кохан М. М., Кениксфест Ю. В., Шайбакова Ю. Б., Полякова Н. В., Топычканова Е. П., Кащеева Я. В. и др. Опыт терапии больных различными формами акне препаратом системного изотретиноина. Клиническая дерматология и венерология. 2014;2:91–99.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Howard R., Smith G. The readability of iPledge program patient education materials. J Am Acad Dermatol. 2018;79(4):e69-e70. DOI: 10.1016/j.jaad.2018.05.038</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Seukeran D. C., Cunliffe W. J. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999 Aug;141(2):307–309. DOI: 10.1046/j.1365-2133.1999.02982.x</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Massa A. F., Burmeister L., Bass D., Zouboulis C. C. Acne Fulminans: Treatment Experience from 26 Patients. Dermatology. 2017;233(2– 3):136–140. DOI: 10.1159/000473860</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Zaenglein A. L., Pathy A. L., Schlosser B. J., Alikhan A., Baldwin H. E., Berson D. S. et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945–973.e33. DOI: 10.1016/j.jaad.2015.12.037</mixed-citation></ref></ref-list></back></article>
